Lincoln Pharmaceuticals
Indian pharmaceutical manufacturer, marketer, and distributor headquartered in Ahmedabad, Gujarat.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Lincoln Pharmaceuticals Limited is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat. Founded in 1979 by Mahendra G. Patel, Rajnikant G. Patel, and Hasmukhbhai I. Patel, the company operates across pharmaceutical manufacturing, product marketing, and distribution. Its business covers a broad range of dosage forms, including tablets, capsules, dry syrups, creams, sterile and non-sterile ointments, dry-powder injections, ampoule injections, liquid vials, eye drops, and oral liquids. The company developed from a Gujarat-based pharmaceutical enterprise into a publicly listed manufacturer with both domestic and international regulatory reach. It launched an initial public offering in 1996 and was listed on the Bombay Stock Exchange. By 2000, its products were reported to be available across approximately 80 percent of the Indian domestic market. Lincoln later expanded its product-development activity through new drug delivery system products and collaborations involving specialized therapies. During 2010–11, it introduced three NDDS products. In cooperation with Switzerland-based Phafag AG, it also introduced Tinnex Injection in India for tinnitus, a condition commonly associated with ringing or other perceived sounds in the ears. Lincoln strengthened its capital-market presence when it joined the National Stock Exchange of India in February 2015. Its product portfolio subsequently included specialized delivery formats such as an ondansetron oral spray, introduced in September 2016 for the prevention of nausea and vomiting associated with chemotherapy, radiation treatment, and surgery. In 2017, the company received an Indian government patent relating to an arteether injection for malaria treatment. Manufacturing and regulatory capability have been central to Lincoln’s development. The company reports manufacturing facilities in Ahmedabad and Mehsana, Gujarat, with operations covering finished pharmaceutical formulations in multiple dosage forms. Its facilities have received ISO 9001:2015 and WHO current Good Manufacturing Practice-related recognition, while particular sites have also obtained approvals or certifications associated with the European Union’s GMP framework and Australia’s Therapeutic Goods Administration. In 2020, the Linits Khatraj facility received European Union GMP certification from EudraGMDP. In 2021, Lincoln acquired a Mehsana plant intended for cephalosporin manufacturing, and the National Company Law Tribunal approved the merger of Lincoln Parenteral with Lincoln Pharmaceuticals. The company’s Gujarat plant also received TGA certification in October of that year. Lincoln describes its portfolio as containing more than 1,700 product registrations, with products registered in multiple overseas markets and a further pipeline of approximately 700 products. The business therefore combines established domestic formulation sales with export-oriented registration, manufacturing, and regulatory activities. Publicly available reference material identifies the company as active and listed, but does not provide enough verified information here to describe current management, revenue, ownership structure, or a definitive present-day geographic sales breakdown.
History
Lincoln Pharmaceuticals was established in Ahmedabad, Gujarat, in 1979 by Mahendra G. Patel, Rajnikant G. Patel, and Hasmukhbhai I. Patel. The company was created as a pharmaceutical manufacturing and marketing business and subsequently expanded into distribution and international product registration. Its early development centered on building a presence in India’s formulation market. A major corporate milestone occurred in 1996, when Lincoln launched an initial public offering and became listed on the Bombay Stock Exchange. By 2000, its products were reported to reach approximately 80 percent of the Indian domestic market. The company later broadened its development program through new drug delivery system products, launching three NDDS products during 2010–11. It also entered a collaboration with Switzerland-based Phafag AG to launch Tinnex Injection in India for tinnitus. Lincoln’s public-market profile expanded further in February 2015 when its shares were listed on the National Stock Exchange of India. Product innovation continued in 2016 with the introduction of an ondansetron oral spray. The product was designed to help prevent nausea and vomiting associated with chemotherapy, radiation therapy, and surgical procedures. In 2017, Lincoln received an Indian government patent for an arteether injection intended for malaria treatment. Manufacturing quality and regulatory approvals became increasingly important to the company’s international strategy. Lincoln operates manufacturing facilities in Ahmedabad and Mehsana, Gujarat, and produces a wide range of pharmaceutical dosage forms, from solid oral medicines to sterile products, injections, ophthalmic products, and oral liquids. The company reports ISO 9001:2015 and WHO cGMP-related credentials, while its facilities have also been associated with regulatory approvals from European and Australian authorities. In May 2020, Lincoln’s Linits Khatraj facility received European Union GMP certification through EudraGMDP. In 2021, the company acquired a Mehsana facility to manufacture cephalosporin products. The same year, the National Company Law Tribunal approved the merger of Lincoln Parenteral with Lincoln Pharmaceuticals, consolidating the related business structure. In October 2021, a Gujarat facility received certification from Australia’s Therapeutic Goods Administration. The company describes its portfolio as including more than 1,700 product registrations and approximately 700 additional products in its pipeline. Its registered products serve India and overseas markets supported by approvals from multiple national drug authorities. Lincoln has also received recognition including the Gujarat SME Excellence Award. The available reference material does not establish current executive leadership, detailed financial performance, or the company’s present ownership structure.
- 2021
Mehsana plant acquisition and corporate merger
[1]Lincoln acquired a Mehsana plant for cephalosporin production, and the National Company Law Tribunal approved the merger of Lincoln Parenteral with Lincoln Pharmaceuticals.
- 2020
European Union GMP certification
[1]The Linits Khatraj facility received European Union GMP certification.
- 2015
National Stock Exchange listing
[1]Lincoln Pharmaceuticals was listed on the National Stock Exchange of India in February.
- 2010
NDDS product launches
[1]Lincoln launched three new drug delivery system products during 2010–11.
- 2000
Expansion across the Indian domestic market
[1]Company products were reported to be available across approximately 80 percent of the Indian domestic market.
- 1996
Initial public offering and Bombay Stock Exchange listing
[1]The company launched an IPO and became listed on the Bombay Stock Exchange.
- 1979
Company established in Ahmedabad
[1]Lincoln Pharmaceuticals was founded in Ahmedabad, Gujarat, by Mahendra G. Patel, Rajnikant G. Patel, and Hasmukhbhai I. Patel.
Products and positioning
A broad-based Indian pharmaceutical manufacturer emphasizing formulation diversity, regulated manufacturing, domestic distribution, international product registrations, and export-market compliance.
Injection
Tinnex Injection
An injectable product launched in India in collaboration with Switzerland-based Phafag AG for tinnitus-related treatment. Tinnitus is commonly experienced as ringing or other perceived sounds in the ears.
Oral drug-delivery product · 2016
Ondansetron oral spray
An oral spray formulation introduced in India in 2016 to help prevent nausea and vomiting associated with chemotherapy, radiation therapy, and surgical procedures.
Antimalarial injection
Arteether injection
An arteether injection associated with a patent received from the Indian government in 2017 for treatment of malaria.
Antibiotic formulations · 2021
Cephalosporin products
A manufacturing category supported by the Mehsana facility acquired by Lincoln in 2021. The available reference does not identify individual brands or molecules.
Pharmaceutical formulations
Lincoln pharmaceutical formulations portfolio
The company manufactures a diversified range of formulations, including tablets, capsules, dry syrups, creams, sterile and non-sterile ointments, dry-powder injections, ampoule injections, liquid vials, eye drops, and oral liquids.
Brand decisions
2021
Acquire a Mehsana plant and merge Lincoln ParenteralM&ABackground
Lincoln sought to strengthen manufacturing capacity, including capacity for cephalosporin products, and consolidate its related corporate structure.
Action taken
The company acquired a Mehsana facility and obtained National Company Law Tribunal approval for the merger of Lincoln Parenteral with Lincoln Pharmaceuticals.
Aftermath
The actions expanded the company’s Gujarat manufacturing footprint and consolidated the related entity, although detailed operational or financial outcomes are not provided.
2015
Expand public-market access through NSE listingStrategyBackground
After its earlier Bombay Stock Exchange listing, Lincoln pursued a listing on the National Stock Exchange of India.
Action taken
The company became listed on the NSE in February 2015.
Aftermath
The listing broadened the company’s presence in India’s public equity markets; the available material does not provide further performance details.
Recent events
- Unconfirmed
Lincoln Pharmaceuticals acquires Mehsana facility for planned Cephalosporin expansion[2]
Reported:
Lincoln Pharmaceuticals said it had acquired a facility in Mehsana, Gujarat, and planned to invest Rs. 30 crore in the plant's expansion and modernisation. It expected commercial production of Cephalosporin products by March 2022; that date was a plan, not a reported completed start.
Lincoln Pharmaceuticals launches Chewable Vitamin C + Zinc Tablet in India[3]
Reported:
Lincoln Pharmaceuticals launched its Chewable Vitamin C + Zinc Tablet in India. The company described the tablet as an evidence-based bio-active product combining vitamin C and zinc.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/lincoln-pharmaceuticals · Editorial policy · How profiles are compiled